查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1908621

全球 Keytruda 市场：市场规模、份额和趋势分析（按适应症、支付方、分销管道和地区划分），按细分市场预测（2026-2033 年）

Keytruda Market Size, Share & Trends Analysis Report By Application (Lung Cancer, Breast Cancer, Melanoma, Hodgkin Lymphoma), By Payer (Commercial/Private, Public), By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

Keytruda市场概览

据估计，到 2025 年，全球 Keytruda 市场规模为 313.8 亿美元，预计到 2033 年将达到 249.5 亿美元。

预计从 2026 年到 2033 年，其复合年增长率将为 -3.80%。由于生物相似药竞争加剧和价格压力，Keytruda（Pembrolizumab）的市场前景预计将在专利到期后减弱。

儘管面临诸多挑战，Keytruda 的全球市占率仍在持续成长，尤其是在南美洲和波湾合作理事会(GCC) 地区，这主要得益于其在多种癌症适应症中的广泛应用。在这两个地区，癌症发生率的上升、肿瘤基础设施投资的增加以及先进免疫疗法的普及，都推动了该药物的广泛应用。 Keytruda 是一种领先的免疫查核点抑制剂，已在非小细胞肺癌、黑色素瘤、头颈癌和其他多种恶性肿瘤中展现出显着疗效，其核准适应症在全球范围内不断扩大。临床试验的增加，特别是联合治疗的评估，以及全球对免疫肿瘤学研究的持续投入，进一步增强了其市场韧性。

Keytruda的国际扩张主要得益于其核准适应症的增加，包括在医疗现代化进程加速发展的南美等发展中地区，以及各国政府高度重视高品质癌症治疗的海湾合作委员会（GCC）地区。这些核准涵盖非小细胞肺癌、黑色素瘤、头颈部鳞状细胞癌和尿路上皮癌等疾病，显着扩大了目标患者群体。 Keytruda作为单药疗法和联合治疗的疗效已得到证实，支持其在各种医疗环境中作为一线治疗、晚期疾病治疗和辅助性治疗。目前正在进行的临床研究探索了结直肠癌、三阴性乳癌和肝细胞癌（HCC）的新适应症，这为其进一步增长提供了潜力。将Keytruda纳入生物标记驱动的治疗策略，例如PD-L1表达和肿瘤突变负荷（TMB），可以优化患者筛选，并巩固其在成熟市场和新兴市场精准肿瘤学领域的地位。

联合治疗仍然是KEYTRUDA产业绩效的关键驱动因素，尤其是在南美洲和海湾合作委员会等地区，这些地区的肿瘤科医师正积极采用现代化的多模式治疗方法。 KEYTRUDA与化疗、标靶治疗和其他免疫疗法的协同作用已在进行性和末期癌症中展现出显着的临床疗效。推动联合疗法研究的策略合作不断增强KEYTRUDA的竞争优势。随着这些治疗方法获得更多核准和实际应用认可，KEYTRUDA的生命週期将得以延长，有助于减轻未来生物相似药竞争的影响。这种对联合治疗的重视确保了KEYTRUDA在全球不同市场的临床相关性和商业性永续性。

Keytruda在早期治疗方案中的应用范围扩大是另一个关键成长要素，这一趋势在南美和海湾合作委员会（GCC）地区也同样存在。这些地区的医疗系统正在加速以免疫疗法进行早期疾病管理。 Keytruda传统上仅限于转移性疾病，现在已获准用于第一线、辅助性治疗和辅助性治疗，有助于降低復发风险并提高存活率。 Keytruda核准用于早期非小细胞肺癌、三阴性乳癌和黑色素瘤的治疗，显着扩大了已开发国家和开发中国家的患者群​​体。随着全球肿瘤学家转向更早采用免疫疗法，对Keytruda的需求持续成长，这巩固了公司在专利到期后应对竞争压力的市场地位。

目录

第一章 分析方法和范围

第二章执行摘要

第三章：Keytruda市场：驱动因素、趋势与范围

  • 市场关联性展望
  • 市场动态
  • 商业环境分析
    • 产业分析：波特五力分析
    • PESTLE分析
    • 专利到期分析
    • 定价和报销方案
    • 企业合併、资本交易
    • 学名药和生物相似药的影响

第四章 Keytruda 市场：按适应症分類的业务分析

  • 按适应症分類的市场份额（2025 年和 2033 年）
  • 按适应症分類的市场规模预测和趋势分析（2021-2033）
  • 肺癌
  • 乳癌
  • 恶性黑色素瘤
  • 何杰金氏淋巴瘤
  • 头颈癌
  • 胃癌
  • 尿路上皮癌
  • 其他的

5. Keytruda市场：按支付方分類的业务分析

  • 按支付方分類的市场份额（2025 年和 2033 年）
  • 按支付方分類的市场规模预测和趋势分析（2021-2033 年）
  • 私人保险
  • 民众

6. Keytruda 市场：按分销管道分類的业务分析

  • 按分销管道分類的市场份额（2025 年和 2033 年）
  • 按分销管道分類的市场规模预测和趋势分析（2021-2033）
  • 医院药房
  • 专科药房

第七章 Keytruda 市场：区域估算与趋势分析

  • 按地区分類的市场份额（2025 年和 2033 年）
  • 市场概览：按地区
  • 市场规模预测及趋势分析（2021-2033）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争情势

  • 参与公司概况
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/列表
    • Merck &Co., Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Regeneron Pharmaceuticals, Inc. &Sanofi SA
    • Pfizer Inc. &Seagen Inc.
    • Amgen Inc.
    • Samsung Bioepis Co., Ltd.
    • Bio-Thera Solutions, Ltd.
Product Code: GVR-4-68040-539-2

Keytruda Market Summary

The global Keytruda market size was estimated at USD 31.38 billion in 2025 and is projected to reach USD 24.95 billion by 2033, declining at a CAGR of -3.80% from 2026 to 2033. The market outlook for Keytruda (pembrolizumab) is expected to soften after its patent expiry due to rising biosimilar competition and pricing pressures.

Despite the impending challenges, Keytruda continues to strengthen its global presence, including in South America and the Gulf Cooperation Council (GCC), supported by its broad adoption across numerous cancer indications. In both regions, the increasing prevalence of cancer, growing investment in oncology infrastructure, and wider access to advanced immunotherapies are driving uptake. As a leading immune checkpoint inhibitor, Keytruda has demonstrated strong efficacy in non-small cell lung cancer, melanoma, head and neck cancers, and several other malignancies, leading to a consistent expansion of regulatory approvals worldwide. Its market resilience is further supported by a growing volume of clinical trials, particularly those evaluating combination therapies, as well as sustained global investment in immuno-oncology research.

Keytruda's expansion across international markets, including developing regions such as South America, where healthcare modernization is accelerating, and the GCC, where governments are prioritizing premium cancer care, has been driven largely by its increasing number of approved indications. These approvals, covering conditions such as non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, and urothelial carcinoma, have substantially broadened its eligible patient base. Its demonstrated effectiveness in monotherapy and combination regimens supports use in first-line, advanced, and adjuvant settings across diverse healthcare environments. Continued clinical research exploring new uses in colorectal cancer, triple-negative breast cancer, and hepatocellular carcinoma provides further growth potential. The drug's incorporation into biomarker-driven strategies, including PD-L1 expression and tumor mutational burden, enhances targeted patient selection and solidifies its position within precision oncology across mature and emerging markets.

Combination therapy remains a pivotal driver of Keytruda's industry performance, especially in regions such as South America and the GCC, where oncologists are increasingly adopting modern, multimodal treatment approaches. Its synergy with chemotherapy, targeted agents, and other immunotherapies has shown strong clinical results in aggressive and late-stage cancers. Strategic partnerships aimed at advancing combination trials continue to reinforce Keytruda's competitive advantage. As more of these regimens gain regulatory approval and real-world acceptance, they extend the drug's lifecycle and help mitigate the impact of future biosimilar competition. This focus on combination approaches ensures Keytruda remains clinically relevant and commercially resilient across diverse global markets.

Keytruda's rising use in earlier treatment lines is another major catalyst, with similar trends emerging across South America and the GCC, where healthcare systems are increasingly adopting immunotherapy for early-stage disease management. Originally reserved for metastatic settings, Keytruda now carries approvals for first-line, neoadjuvant, and adjuvant use, helping reduce recurrence risk and improve survival outcomes. Approvals for early-stage non-small cell lung cancer, triple-negative breast cancer, and melanoma have significantly expanded its patient population across both developed and developing markets. As oncologists worldwide shift toward the earlier integration of immunotherapy, demand for Keytruda continues to grow, strengthening its market position ahead of the anticipated competitive pressures following patent expiry.

Global Keytruda Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Keytruda market report based on application, payer, distribution channel, and region:

  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Lung Cancer
  • Breast Cancer
  • Melanoma
  • Hodgkin Lymphoma
  • Head and Neck Cancer
  • Gastric Cancer
  • Urothelial Cancer
  • Others
  • Payer Outlook (Revenue, USD Million, 2021 - 2033)
  • Commercial/Private
  • Public
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacy
  • Specialty Pharmacy
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Payer
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Keytruda Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Patent Expiry Analysis
    • 3.3.4. Pricing and Reimbursement Scenario
    • 3.3.5. M&A and Deals
    • 3.3.6. Impact of Generics/Biosimilars

Chapter 4. Keytruda Market: Application Business Analysis

  • 4.1. Application Market Share, 2025 & 2033
  • 4.2. Application Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 4.4. Lung Cancer
    • 4.4.1. Lung Cancer Market, 2021 - 2033 (USD Million)
  • 4.5. Breast Cancer
    • 4.5.1. Breast Cancer Market, 2021 - 2033 (USD Million)
  • 4.6. Melanoma
    • 4.6.1. Melanoma Market, 2021 - 2033 (USD Million)
  • 4.7. Hodgkin Lymphoma
    • 4.7.1. Hodgkin Lymphoma Market, 2021 - 2033 (USD Million)
  • 4.8. Head and Neck Cancer
    • 4.8.1. Head and Neck Cancer Market, 2021 - 2033 (USD Million)
  • 4.9. Gastric Cancer
    • 4.9.1. Gastric Cancer Market, 2021 - 2033 (USD Million)
  • 4.10. Urothelial Cancer
    • 4.10.1. Urothelial Cancer Market, 2021 - 2033 (USD Million)
  • 4.11. Others
    • 4.11.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Keytruda Market: Payer Business Analysis

  • 5.1. Payer Market Share, 2025 & 2033
  • 5.2. Payer Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Payer, 2021 to 2033 (USD Million)
  • 5.4. Commercial/Private
    • 5.4.1. Commercial/Private Market, 2021 - 2033 (USD Million)
  • 5.5. Public
    • 5.5.1. Public Market, 2021 - 2033 (USD Million)

Chapter 6. Keytruda Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2025 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 6.4. Hospital Pharmacy
    • 6.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)
  • 6.5. Specialty Pharmacy
    • 6.5.1. Specialty Pharmacy Market, 2021 - 2033 (USD Million)

Chapter 7. Keytruda Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Keytruda Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. Canada Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Keytruda Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Merck & Co., Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Bristol-Myers Squibb Company
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. F. Hoffmann-La Roche Ltd.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Regeneron Pharmaceuticals, Inc. & Sanofi S.A.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Pfizer Inc. & Seagen Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Amgen Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Samsung Bioepis Co., Ltd.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Bio-Thera Solutions, Ltd.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Keytruda market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 5 Global Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 6 Global Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 7 Global Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 8 North America Keytruda market, by country, 2021 - 2033 (USD Million)
  • Table 9 North America Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 10 North America Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 11 North America Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 12 North America Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13 US Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 14 US Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 15 US Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 16 US Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Canada Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 18 Canada Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 19 Canada Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 20 Canada Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 21 Mexico Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 22 Mexico Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 23 Mexico Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 24 Mexico Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 25 Europe Keytruda market, by country, 2021 - 2033 (USD Million)
  • Table 26 Europe Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 27 Europe Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 28 Europe Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 29 Europe Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 UK Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 31 UK Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 32 UK Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 33 UK Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34 Germany Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 35 Germany Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 36 Germany Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 37 Germany Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 38 France Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 39 France Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 40 France Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 41 France Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 Italy Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 43 Italy Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 44 Italy Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 45 Italy Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 46 Spain Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 47 Spain Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 48 Spain Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 49 Spain Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 50 Norway Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 51 Norway Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 52 Norway Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 53 Norway Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54 Denmark Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 55 Denmark Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 56 Denmark Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 57 Denmark Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 58 Sweden Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 59 Sweden Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 60 Sweden Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 61 Sweden Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 62 Asia-Pacific Keytruda market, by country, 2021 - 2033 (USD Million)
  • Table 63 Asia-Pacific Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 64 Asia-Pacific Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 65 Asia-Pacific Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 66 Asia-Pacific Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 67 Japan Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 68 Japan Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 69 Japan Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 70 Japan Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 71 China Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 72 China Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 73 China Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 74 China Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 75 India Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 76 India Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 77 India Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 78 India Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 79 Australia Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 80 Australia Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 81 Australia Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 82 Australia Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 83 South Korea Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 84 South Korea Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 85 South Korea Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 86 South Korea Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87 Thailand Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 88 Thailand Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 89 Thailand Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 90 Thailand Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 91 Latin America Keytruda market, by country, 2021 - 2033 (USD Million)
  • Table 92 Latin America Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 93 Latin America Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 94 Latin America Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 95 Brazil Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 96 Brazil Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 97 Brazil Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 98 Brazil Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 99 Argentina Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 100 Argentina Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 101 Argentina Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 102 Argentina Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 103 Middle East & Africa (MEA) Keytruda market, by country, 2021 - 2033 (USD Million)
  • Table 104 Middle East & Africa Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 105 Middle East & Africa Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 106 Middle East & Africa Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 107 Middle East & Africa Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 108 South Africa Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 109 South Africa Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 110 South Africa Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 111 South Africa Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 112 Saudi Arabia Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 116 UAE Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 117 UAE Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 118 UAE Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 119 UAE Keytruda market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 120 Kuwait Keytruda market, by type, 2021 - 2033 (USD Million)
  • Table 121 Kuwait Keytruda market, by application, 2021 - 2033 (USD Million)
  • Table 122 Kuwait Keytruda market, by dosage form, 2021 - 2033 (USD Million)
  • Table 123 Kuwait Keytruda market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Keytruda market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Keytruda market dynamics
  • Fig. 12 Keytruda market: Porter's five forces analysis
  • Fig. 13 Keytruda market: PESTLE analysis
  • Fig. 14 Keytruda market revenue by application (2021 - 2033)
  • Fig. 15 Lung cancer market outlook (USD Million)
  • Fig. 16 Breast cancer market growth trend (USD Million)
  • Fig. 17 Melanoma treatment market analysis (USD Million)
  • Fig. 18 Hodgkin lymphoma treatment market size (USD Million)
  • Fig. 19 Head and neck cancer Keytruda market share (USD Million)
  • Fig. 20 Gastric cancer Keytruda market revenue (USD Million)
  • Fig. 21 Urothelial cancer Keytruda market demand (USD Million)
  • Fig. 22 Other cancer applications for Keytruda (USD Million)
  • Fig. 23 Keytruda market revenue by payer type (2021 - 2033)
  • Fig. 24 Commercial/private insurance market share for Keytruda (USD Million)
  • Fig. 25 Public insurance market growth for Keytruda (USD Million)
  • Fig. 26 Keytruda market revenue by distribution channel (2021 - 2033)
  • Fig. 27 Hospital pharmacy Keytruda market analysis (USD Million)
  • Fig. 28 Specialty pharmacy Keytruda market growth trend (USD Million)
  • Fig. 29 Keytruda market revenue, by region
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 North America Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. country dynamics
  • Fig. 33 U.S. Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 34 Canada country dynamics
  • Fig. 35 Canada Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 36 Mexico country dynamics
  • Fig. 37 Mexico Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 38 Europe Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 39 UK country dynamics
  • Fig. 40 UK Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 41 Germany country dynamics
  • Fig. 42 Germany Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 43 France country dynamics
  • Fig. 44 France Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 45 Italy country dynamics
  • Fig. 46 Italy Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 47 Spain country dynamics
  • Fig. 48 Spain Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 49 Norway country dynamics
  • Fig. 50 Norway Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 51 Sweden country dynamics
  • Fig. 52 Sweden Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 53 Denmark country dynamics
  • Fig. 54 Denmark Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 55 Asia-Pacific Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 56 Japan country dynamics
  • Fig. 57 Japan Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 58 China country dynamics
  • Fig. 59 China Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 60 India country dynamics
  • Fig. 61 India Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 62 Australia country dynamics
  • Fig. 63 Australia Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 64 South Korea country dynamics
  • Fig. 65 South Korea Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 66 Thailand country dynamics
  • Fig. 67 Thailand Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 68 Latin America Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 69 Brazil country dynamics
  • Fig. 70 Brazil Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 71 Argentina country dynamics
  • Fig. 72 Argentina Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 73 Middle East & Africa (MEA) Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 74 South Africa country dynamics
  • Fig. 75 South Africa Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 76 Saudi Arabia country dynamics
  • Fig. 77 Saudi Arabia Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 78 UAE country dynamics
  • Fig. 79 UAE Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 80 Kuwait country dynamics
  • Fig. 81 Kuwait Keytruda market, 2021 - 2033 (USD Million)
  • Fig. 82 Company categorization
  • Fig. 83 Company market position analysis
  • Fig. 84 Strategic framework